Search clinical trials for: Ado-Trastuzumab Emtansine

Total 3563 results

National Cancer Institute (NCI)

Active, not recruiting

Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
Jenny C. Chang, MD
Genentech, Inc.; The Methodist Hospital Research Institute

Withdrawn

Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast Cancer (NATURE)

Breast Cancer

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Withdrawn

T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | HER2 Positive Breast Carcinoma | Metastatic Breast Carcinoma

United States
Spectrum Pharmaceuticals, Inc

Terminated

A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer

Breast Cancer

United States
Daiichi Sankyo
AstraZeneca; Daiichi Sankyo Co., Ltd.

Active, not recruiting

DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

Breast Cancer

United States, Canada, Spain, Belgium, China, Italy, Korea, Republic of, Taiwan, Australia, Japan, Brazil, France, Germany, United Kingdom, Hong Kong
Medstar Health Research Institute
Genentech, Inc.

Completed

Cardiac Safety Study in Patients With HER2 + Breast Cancer (SAFE-HEaRt)

Left Ventricular Function Systolic Dysfunction | HER2 Positive Breast Cancer

United States
University of Washington
National Cancer Institute (NCI)

Completed

Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | HER2/Neu Positive

United States
M.D. Anderson Cancer Center
Genentech, Inc.; Seagen Inc.

Recruiting

A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)

Metastatic Solid Tumor | Brain Metastases

United States
Memorial Sloan Kettering Cancer Center
Genentech, Inc.

Recruiting

Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers

Lung Cancer | Bladder Cancer | Solid Tumor Cancers | Urinary Tract Cancers

United States
Hoffmann-La Roche
Roche Pharma AG

Completed

A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab

Metastatic Breast Cancer

Italy, Spain, Canada, United States, Belgium, France, Germany
Hoffmann-La Roche

Completed

A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function

Breast Cancer

United States, Canada, Spain, France, Italy
Dana-Farber Cancer Institute
Merck Sharp & Dohme LLC

Active, not recruiting

A Study Of Pembrolizumab In Combination With Trastuzumab-DM1

Breast Cancer

United States
Western Regional Medical Center

Terminated

Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer (PembroMab)

Breast Cancer | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Advanced Cancer

United States
Consorzio Oncotech
Roche Pharma AG

Recruiting

Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target Therapy

Breast Cancer

Italy
Hoffmann-La Roche

Terminated

A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer

Gastric Cancer

United States, China, Korea, Republic of, Canada, Belgium, Brazil, Finland, Guatemala, Italy, Poland, Spain, Turkey, United Kingdom, Czechia, Hungary, Russian Federation, Argentina, France, Germany, Japan, Malaysia, Mexico, Panama, Peru, Philippin... and more
Hoffmann-La Roche

Completed

A Study of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a Taxane

HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer

India
Jules Bordet Institute

Withdrawn

Kadcyla In pAtients With bRAin Metastasis (KIARA)

Metastatic HER2-positive Breast Cancer With Brain Metastasis
Hoffmann-La Roche

Completed

Study of the Pharmacokinetics and Safety of Trastuzumab Emtansine in Chinese Participants With Locally Advanced Inoperable or Metastatic HER2+ Breast Cancer

Breast Neoplasms

China
Genentech, Inc.

Completed

A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer

Metastatic Breast Cancer

United States
Genentech, Inc.

Completed

A Study of Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer

Metastatic Breast Cancer
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer

Advanced Breast Cancer | Metastatic Breast Cancer

China
Hoffmann-La Roche

Terminated

A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast Cancer

Metastatic Breast Cancer

Taiwan, Korea, Republic of, Thailand, Malaysia
Hoffmann-La Roche

Completed

A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Breast Cancer

Italy, Belgium, Canada, United Kingdom, Argentina, Australia, Austria, Brazil, Bulgaria, China, Croatia, Denmark, Dominican Republic, Ecuador, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, Indonesia, Irelan... and more
Fondazione del Piemonte per l'Oncologia

Unknown

Study of Trastuzumab-emtansine in Patients With HER2-positive Metastatic Colorectal Cancer Progressing After Trastuzumab and Lapatinib. (RESCUE)

Metastatic Colorectal Cancer

Italy
Hoffmann-La Roche

Completed

A Study of Trastuzumab Emtansine (T-DM1) Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage Herceptin (HER)2-positive Breast Cancer

Breast Cancer

Spain, United States, France, Germany, Belgium, Korea, Republic of, Italy, Russian Federation
Hoffmann-La Roche
NSABP Foundation Inc; German Breast Group

Active, not recruiting

A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

Breast Cancer

United States, Italy, United Kingdom, Canada, Czechia, Argentina, Austria, Belgium, Brazil, China, France, Germany, Guatemala, Ireland, Panama, Spain, Sweden, Taiwan, Turkey, Colombia, Hong Kong, Peru, Switzerland, South Africa, Israel, G... and more
Hoffmann-La Roche

Completed

A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease

Breast Cancer
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Phase II Clinical Study of T-DM1 and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer Who Had Progressed on TKI Therapy

HER2+ Advanced Breast Cancer Patients Progressing on TKI Therapy
Hoffmann-La Roche

Completed

A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors (KAMELEON)

Bladder Cancer | Pancreas Cancer | Cholangiocellular Carcinoma

Spain, Italy, Netherlands, Slovakia
Hoffmann-La Roche

Completed

A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

United States, Italy, Korea, Republic of, Spain, Germany, Poland, Switzerland
Hoffmann-La Roche

Terminated

A Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer

Breast Cancer

Korea, Republic of, Australia
xuexin he

Recruiting

A Study of HER2+ Breast Cancer Patients With Active Brain Metastases Treated With Afatinib & T-DM1 vs. T-DM1 Alone (HER2BAT)

HER2-positive Breast Cancer | Brain Metastases

China
The Netherlands Cancer Institute
Roche Pharma AG; AstraZeneca

Terminated

T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC (TRAEMOS)

Carcinoma, Non-Small-Cell Lung

Netherlands
Hoffmann-La Roche

Completed

A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast Cancer

Breast Cancer

Spain, France, United States, United Kingdom
Cancer Trials Ireland

Terminated

Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer (Panthera)

Metastatic Breast Cancer | HER2-positive Breast Cancer | Locally Advanced Breast Cancer | Unresectable Breast Cancer

Ireland, Spain
University of Miami
Genentech, Inc.

Terminated

Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer

Breast Cancer | Metastatic Breast Cancer

United States
Fondazione del Piemonte per l'Oncologia

Unknown

Evaluation of Trastuzumab in Combination With Lapatinib or Pertuzumab in Combination With Trastuzumab-Emtansine to Treat Patients With HER2-positive Metastatic Colorectal Cancer (HERACLES)

Metastatic Colorectal Cancer

Italy
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer (ProHer)

Inflammatory Breast Cancer | Early Breast Cancer | Locally Advanced Breast Cancer

Canada, Croatia, Spain, Argentina, Mexico, Korea, Republic of, Bosnia and Herzegovina, Brazil, Costa Rica, Turkey, Singapore, Bulgaria, South Africa, India, Peru, Kenya, Chile
Daiichi Sankyo, Inc.
AstraZeneca; NSABP Foundation Inc; German Breast Group; Spanish Breast Cancer Research...

Active, not recruiting

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

HER2-Positive Primary Breast Cancer | Residual Invasive Breast Cancer

United States, Spain, France, Germany, Korea, Republic of, United Kingdom, Denmark, Israel, Belgium, Taiwan, Chile, Italy, Japan, Peru, Portugal, China, Turkey, Canada, Ireland, Australia, Greece, Czechia, Singapore, Poland, Romania, Arge... and more
Swiss Group for Clinical Cancer Research

Completed

Trastuzumab & Pertuzumab Followed by T-DM1 in MBC

Metastatic Breast Cancer

France, Switzerland, Netherlands, Germany
Hoffmann-La Roche

Recruiting

A Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast Cancer

Breast Cancer

China
National Cancer Institute (NCI)

Terminated

BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)

Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Hormone Receptor Negative Breast Cancer | HER2+ Breast Cancer

United States
Genentech, Inc.

Completed

A Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received a Trastuzumab-Containing Regimen

Metastatic Breast Cancer
Genentech, Inc.

Completed

Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression

Metastatic Breast Cancer
Hoffmann-La Roche

Completed

A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy (KATE2)

Metastatic Breast Cancer

United States, Korea, Republic of, United Kingdom, Germany, Spain, Taiwan, Australia, Canada, Italy
Dana-Farber Cancer Institute
Genentech, Inc.

Recruiting

ATEMPT 2.0: Adjuvant T-DM1 vs TH

Breast Cancer | HER2-positive Breast Cancer

United States
MedSIR
Hoffmann-La Roche

Active, not recruiting

Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer (PHERGAIN-2)

Early Breast Cancer

Spain, Italy, Germany, Bulgaria, Hungary
N.N. Petrov National Medical Research Center of...

Recruiting

Stereotactic Radiation Therapy for HE2-positive Oligometastatic Breast Cancer

Oligometastatic Disease | HER2-positive Metastatic Breast Cancer

Russian Federation
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy

Advanced Breast Cancer | Objective Response Rate | Trastuzumab Emtansine

China
Hoffmann-La Roche

Terminated

A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/mGC) (TRAXHER2)

Breast Cancer | Gastric Cancer

Italy, Argentina, Canada, France, Greece, Portugal, Slovakia, Brazil, Russian Federation, Spain, Germany, Serbia

3

Subscribe